Business
Easton Pharmaceuticals Announces It Has Moved Toward Signing Sales & Distribution Agreement With Women's Health-Focused Multi-National European Pharma Company for Its VS-Sense, AL-Sense and Gynofit Products
Easton Pharmaceuticals Announces It Has Moved Toward Signing Sales & Distribution Agreement With Women's Health-Focused Multi-National European Pharma Company for Its VS-Sense, AL-Sense and Gynofit Products.
About this update from Easton Pharmaceuticals Inc
[{"type":"text","content":"\n \n \n Easton Pharmaceuticals Announces It Has Moved Toward Signing Sales & Distribution Agreement With Women's Health-Focused Multi-National European Pharma Company for Its VS-Sense, AL-Sense and Gynofit Products\n \n \nEaston Pharmaceuticals Announces It Has Moved Toward Signing Sales & Distribution Agreement With Women's Health-Focused Multi-National European Pharma Company for Its VS-Sense, AL-Sense and Gynofit Products\n \n TORONTO, ON--(Marketwired - May 10, 2016) - Easton Pharmaceuticals Inc. (OTC PINK: EAPH), together with their commercial alliance partner BMV Medica SA de CV announces it has initiated partnership negotiations for Mexico and Latin American Sales & Marketing of its suite of women's health products with a multi-national Europe-based Pharma company, currently operating in over 38 countries world-wide.\n Easton and its partner BMV Medica S.A de C.V have been in formal discussions over the last several months with a Europe-based Multi-National Pharma company who currently has a successful foothold within 38 countries, including Mexico, with specialized Women's Health products. The negotiations have progressed well with interest being high, which has now resulted with both companies moving toward signing a final agreement whereby this company would use its large marketing and distribution resources to take over and spearhead all marketing and distribution of Easton/BMV's VS-Sense, AmnioSense and Gynofit products beginning with Mexico. A final agreement would most likely be executed with the products being launched in stages starting with Gynofit as its first product launch. The regulatory approvals for the VS-Sense and AL-Sense products from the Mexican Ministry of Health is imminent with Gynofit already approved for sale. Although Easton is not at liberty at this time to disclose terms or names, the European multi-national company currently has sales in the Billions of Dollars throughout 38 countries. A partnership with such a company would provide Easton Pharmaceuticals with a significant increase in projected sales than if Easton was to proceed alone. Current projections from the European based company have sales for Gynofit alone at $7,000,000 within 12 months of product launch.\n Easton/BMV were notified through Ackerman Pharma, the filing of its patented, point-of-care, VS-Sense Diagnostic ...